Lulu Wang, Haixia Fu, Yazhen Qin, Xiaosu Zhao, Peng Zhao, Zhuoyu An, Yun He, Qiusha Huang, Yuhong Chen, Meng Lv, Jun Kong, Zhidong Wang, Wei Han, Yuanyuan Zhang, Xiaodong Mo, Tingting Han, Chenhua Yan, Yingjun Chang, Fengrong Wang, Xiangyu Zhao, Yu Wang, Lanping Xu, Xiaojun Huang, Xiaohui Zhang
KMT2A partial tandem duplication (KMT2A-PTD) is a recurrent genetic alteration in acute myeloid leukemia (AML), but its role as a measurable residual disease (MRD) marker before allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains unclear. We retrospectively analyzed 180 KMT2A-PTD AML patients undergoing allo-HSCT at Peking University People's Hospital between 2015 and 2025. Pre-transplant KMT2A-PTD MRD was quantified by real-time quantitative PCR, with positivity defined as ≥1500 copies/10⁵ ABL1. Among 158 patients transplanted in complete remission (CR), 144 had pre-transplant MRD assessment, and 34 (24%) were MRDpositive. Compared with MRD-negative patients, MRD-positive patients had significantly inferior 3- year overall survival (OS, 49% vs. 80%; p.